patients with advanced gastric cancer (AGC): limited treatment, maintenance of some drugs or treatment until progression.

Purpose Assess prognostic factors and progression-free survival (PFS) in each stratum established according to the duration of the treatment.

Material and methods The sample comprises patients from the AGAMENON multicentre registry in which 31 Spanish and one Chilean centre participated. The eligibility criteria include adults (≥ 18 years) with a histologically confirmed unresectable or AGC and first-line polychemotherapy without progression in the second evaluation of response at approximately 6 months. Multi-state models were used to model processes in which participants undergo transitions from one state to another (e.g., from initiation to cessation of drugs, and from that point to progression or death). In order to examine time-varying states, a Markov multi-state model was used. On the cumulative scale, the transition probability matrix was established by the Aalen-Johansen estimator.

Results We analysed 415 patients treated between January 2008 and September 2017. The patients were divided into three strata: discontinuation of platinum and maintenance with fluoropyrimidine until progression (30%, $n=123$); complete treatment withdrawal prior to progression (52%, $n=216$); and full treatment until progression (18%, $n=76$). Compared to those receiving treatment until progression, no decrease in PFS was observed in participants who discontinued all treatment (HR 1.16, 95% CI, 0.70 to 1.92) or in whom platinum was suspended (HR 0.92, 95% CI, 0.54 to 1.58). With respect to PFS prognostic factors, a significant effect was observed for ECOG ≥ 2 in stratum 3 (HR 4.06, 95% CI, 1.40 to 11.7). The presence of ≥ 3 metastatic sites revealed a prognostic effect after discontinuing platinum (HR 1.65, 95% CI, 1.06 to 2.56) or all chemotherapy (HR 1.65, 95% CI, 1.06 to 2.56). Bone metastases were an adverse prognostic factor in all the strata (HR 1.64, 95% CI, 1.13 to 2.37). Complete response was a protective factor after withdrawing the entire regimen (HR 0.31, 95% CI, 0.16 to 0.57) or platinum (HR 0.12, 95% CI, 0.03 to 0.41). No significant interactions between covariates were detected.

Conclusion In this registry of AGC, treating until progression did not impact PFS compared to maintenance or discontinuation after a predefined number of cycles.

REFERENCES AND/OR ACKNOWLEDGEMENTS

We thank all the researchers of the AGAMENON registry.

No conflict of interest.

4CPS-107 EFFECTIVENESS AND SAFETY STUDY OF NIVOLUMAB IN THE SECOND LINE OF ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER

M Camean-Castillo*, C Martínez-Díaz, MD Gil-Sierra, MP Briceño-Casado, FJ Salmeron-Navas, S Fenix-Caballero, J Díaz-Navarro, E Ríos-Sánchez, EJ Alegre-Del Rey, JM Borrero-Rubio. *H.U. Puerto Real, Pharmacy, Cádiz, Spain*

10.1136/ejhp-2019-eahpconf.256

Background After the approval of nivolumab some time ago it is necessary to analyse if the results of the randomised clinical trials are correlated with usual clinical practice.

Purpose In this study we assessed median progression-free survival, overall survival and safety in patients diagnosed with advanced nonsquamous non-small cell lung cancer who received the second line of treatment with nivolumab monotherapy in our hospital, comparing it with the results of the pivotal trial.

Material and methods A retrospective and descriptive review of patients treated with nivolumab in our centre from January 2016 to September 2018 was done. The patients received 3 mg/kg every 14 days. The following variables were collected from the unified clinical history and the cytostatic management programme: nonsquamous non-small cell lung cancer diagnosis, sex and performance status. The progression-free survival and overall survival curve was constructed using the Kaplan-Meier method, from which the median was obtained and compared to the pivotal trial (CheckMate 057). The main adverse events were collected.

Results Twenty-five patients were treated in the second line with advanced nonsquamous non-small cell lung cancer with nivolumab of whom 80% was male. Performance status was 0, 1 or 2 in 28%, 68% and 4% patients respectively. Median progression-free survival reached was 5.5 months, which was 3.2 months higher than the trial (2.3 months). Median overall survival reached was 12 months which was 0.2 months lower than the trial (12.2 months). The most prevalent adverse events were asthenia (44%), nausea (20%) and diarrhoea (12%). There were two patients with grade 3 asthenia, one patient with alanine aminotransferase increased grade 3 and one patient with pneumonitis.

Conclusion The effectiveness obtained measured with median progression-free survival was higher than that of the pivotal trial, and analogous measured as overall survival, however we must take into account the limitations of a study with a low number of patients. A small percentage of patients present adverse events grade 3.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

4CPS-108 DABRAFENIB AND TRAMETINIB: COMBINATION THERAPY FOR METASTATIC MELANOMA

C Carriles Fernández*, A Arias, C Rosado María, I Zapico García, B Zarate Tamames, R Menárguez Blanc, A Lozano-Blázquez. *Hospital Universitario Central de Asturias, Pharmacy, Oviedo, Spain*

10.1136/ejhp-2019-eahpconf.257

Background The BRAF inhibitor dabrafenib and the MEK inhibitor trametinib are indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF (V600) mutation. The combination of both drugs has shown more effectiveness and an increase in survival. These are used in first-line treatment for patients with mutated BRAF, and in the second line for patients with no-mutated BRAF.

Purpose To evaluate the effectiveness and tolerability of both dabrafenib and trametinib, based on the overall survival (OS) and progression-free survival (PFS) for metastatic melanoma.

Material and methods Retrospective study that included patients receiving a combination of dabrafenib and trametinib. The period of study was from May 2015 until 30 September 2018 (end of study). The required data was obtained from clinical electronic history Cerner Millennium and the variables